ClinicalTrials.gg
RecruitingNCT04971720PRECISION-BPUpdated Apr 9, 2026

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

A Phase 2/3 interventional study of Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet and Valsartan 80 mg Oral Tablet in Obesity, Cardiovascular Diseases and Hypertension, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by University of Alabama at Birmingham · Phase 2/3, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Obesity by University of Alabama at Birmingham — 13 open to participants now, 17 under way, 1 of them phase 3. Obesity · University of Alabama at Birmingham.

Planned enrollment
16th of 70
160 · median 56
Started
2022
with 4 others
Phase 2/3
Only one
of the 77
Primary completion
2027-01
later than 6 of 16 live
Registered
50th of 77
by date

Among the 77 studies in Obesity by University of Alabama at Birmingham, this one is the 16th largest by planned enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2022, is the only one in phase 2/3, reaches primary completion later than 6 of the 16 other live ones, and was the 50th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 77 studies in Obesity by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Obesity by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death. Natriuretic Peptides (NPs) are hormones produced by the heart which directly regulate BP by causing dilation of blood vessels and by removing sodium and water from the body. NPs have a 24-hour day-night rhythm and this controls the day-night rhythm of BP as well. The NP-BP rhythm relationship is broken down in obese individuals. Obese individuals also have lower circulating NP levels. Lower circulating levels of NPs and elevated renin hormone (a part of the Renin-Angiotensin-Aldosterone System [RAAS]) at nighttime may contribute to the high nocturnal blood pressure in obese individuals which puts them at a higher risk of developing CV events. This current study seeks to determine the biological implications of chronopharmacology for synchronizing NP-RAAS-based blood pressure therapy with the physiological diurnal rhythms to restore the normal diurnal rhythm of blood pressure in obese individuals.

Read the detailed description

The investigators have demonstrated that there exists a diurnal rhythm of natriuretic peptides (NPs) which tracks closely with the BP rhythm and is in an antiphase relationship with the rhythm of the RAAS (Renin-Angiotensin-Aldosterone System) hormones. The NP levels are lowest at night, and the renin and aldosterone levels are highest at nighttime. Furthermore, the investigators have demonstrated that obese individuals have a putative deficiency of NPs, and this is due to decreased production alongside increased clearance of NPs. LCZ696 is an FDA-approved inhibitor of neprilysin (an NP degrading enzyme) that augments the NP levels and also suppresses the RAAS. Hence, the confluence of putative NP deficiency among obese alongside the lower levels of NPs at nighttime and the increased activity of RAAS at night may contribute to the high-risk nocturnal non-dipping BP profile among obese individuals. Chronopharmacology (controlling the time of medication administration) to synchronize the NP-RAAS axis targeting anti-hypertensive medications with the inherent biological NP-RAAS-BP rhythm axis may help in controlling the high-risk nocturnal BP non-dipping in obese. Investigators hypothesize that nighttime administration of NP augmenting and/or RAAS inhibition therapy in obese hypertensive individuals will help to improve their nocturnal BP rhythm. The investigators aim to conduct a patient-oriented physiological clinical trial to assess the effect of timing of administration of NP-RAAS axis therapy on restoring the normal BP rhythm. This study is a 2x2 factorial design trial, wherein individuals will be randomized to either daytime dosing or nighttime dosing of either LCZ696 or valsartan. The investigators will study the effect of timing of NP augmenting and/or RAAS inhibiting therapy on the nighttime BP profile in obese hypertensive patients with nondipping nocturnal BP. The investigators will also assess the effect of NP augmentation in an NP deficient population on the nocturnal BP profile, i.e., in obese hypertensives with nondipping nocturnal BP. The investigators will also examine the impact of NP augmenting-RAAS inhibiting therapy on the NP levels and the physiological diurnal rhythms.

This study will assess the physiological implications of chronopharmacology of anti-hypertensive therapy and assess a potentially novel approach of using the inherent biological rhythms to reduce the normal BP rhythmicity in a high-risk population

03

Conditions studied

  • Obesity
  • Cardiovascular Diseases
  • Hypertension
  • Nocturnal Blood Pressure
  • Natriuretic Peptides
  • Renin-Angiotensin-Aldosterone System

Keywords

  • Natriuretic Peptides
  • Nocturnal Blood Pressure
  • Renin-Angiotensin-Aldosterone System
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age more than or equal to 18 years of age
  • between 30 to 45 kg/m\^2
  • Blood pressure: Systolic BP more than or equal to 130mmHg and less than or equal to 160mmHg and diastolic blood pressure more than or equal to 80mmHg and less than or equal to 100mmHg. Individuals with hypertension as per the 2017 ACC/AHA Guidelines will be eligible for enrollment

Exclusion criteria

Exclusion Criteria:

  • Age less than 18, at screening.
  • Systolic BP \<130 or >160mmHg at baseline, or diastolic BP \<80 or >100 mmHg at baseline
  • \<30 kg/m\^2 or >45 kg/m\^2
  • History of pulmonary hypertension
  • Have any past or present illness of cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, diabetes, stroke, , or seizure.
  • Participants who are taking 3 or more classes of hypertension medications on the maximum dose or with resistant hypertension
  • History of angioedema
  • Estimated (GFR) \< 60 ml/min/1.73 m2 (CKD-EPI equation); urine albumin creatinine ratio ≥30 mg/g
  • Hepatic Transaminase ( and ALT) levels >3x the ;
  • Significant psychiatric illness
  • Anemia (men, Hct \< 38%; women, Hct \<36%)
  • Participants working night shifts or swing shifts
  • Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of during the study (including abstinence)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Sacubitril/Valsartan Morning Dose

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Drug: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet

  • Experimental
    Sacubitril/Valsartan Evening Dose

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Drug: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet

  • Active comparator
    Valsartan Morning Dose

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Drug: Valsartan 80 mg Oral Tablet

  • Active comparator
    Valsartan Evening Dose

    We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the evening and a placebo pill in the morning for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.

    Drug: Valsartan 80 mg Oral Tablet

Interventions

  • DrugSacubitril-Valsartan 49 Mg-51 Mg Oral Tablet

    The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.

    Also known as: Sacubitril/Valsartan

  • DrugValsartanStudies of ValsartanValsartan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.

    Also known as: Valsartan

06

What researchers measure

Primary outcomes

  1. Change in mean nocturnal systolic blood pressure

    Change in mean nocturnal systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention.

Secondary outcomes

  1. Change in percent nocturnal dipping blood pressure

    Change in percent nocturnal dipping blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention.

  2. Change in 24-hour mean systolic blood pressure

    Change in 24-hour mean systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention.

  3. Change in 24-hour mean diastolic blood pressure

    Change in 24-hour mean diastolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention.

  4. Change in mean daytime systolic blood pressure

    Change in mean daytime systolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  5. Change in mean daytime diastolic blood pressure

    Change in mean daytime diastolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  6. Change in mean nocturnal diastolic blood pressure

    Change in mean nocturnal diastolic blood pressure will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention.

  7. Change in the daytime, nocturnal, and total urinary excretion parameters (Urine Sodium, Urine Potassium, Urine Creatinine, Urine Albumin).

    Change in the daytime, nocturnal, and total urinary excretion parameters (Urine Sodium, Urine Potassium, Urine Creatinine, Urine Albumin) will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  8. Change in 24-hour, daytime, and nocturnal ANP, BNP, NTproBNP, and renin levels

    Change in 24-hour, daytime, and nocturnal ANP, BNP, NTproBNP, and renin levels will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  9. Change in 24-hour, daytime, and nocturnal MRproANP levels

    Change in 24-hour, daytime, and nocturnal MRproANP levels will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  10. Change in 24-hour, daytime, and nocturnal Aldosterone levels

    Change in 24-hour, daytime, and nocturnal Aldosterone levels will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  11. Change in rhythm parameters (mesor, amplitude, and phase) for ANP, BNP, NTproBNP, renin, and melatonin rhythms.

    Change in rhythm parameters (mesor, amplitude, and phase) for ANP, BNP, NTproBNP, renin, and melatonin rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  12. Change in rhythm parameters (mesor, amplitude, and phase) for MRproANP.

    Change in rhythm parameters (mesor, amplitude, and phase) for MRproANP will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  13. Change in rhythm parameters (mesor, amplitude, and phase) for aldosterone rhythms.

    Change in rhythm parameters (mesor, amplitude, and phase) for aldosterone rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  14. Change in rhythm parameters (mesor, amplitude, and phase) for cortisol rhythms.

    Change in rhythm parameters (mesor, amplitude, and phase) for cortisol rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

  15. Change in rhythm parameters (mesor, amplitude, and phase) for systolic BP, and diastolic BP rhythms.

    Change in rhythm parameters (mesor, amplitude, and phase) for systolic BP, and diastolic BP rhythms will be analyzed in the two study arms (morning vs. evening dose of sacubitril/valsartan or valsartan) from baseline and after 28 days of intervention.

    Time frame: At Baseline and after 28 days of intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Parcha V, Patel N, Gutierrez OM, Li P, Gamble KL, Musunuru K, Margulies KB, Cappola TP, Wang TJ, Arora G, Arora P. Chronobiology of Natriuretic Peptides and Blood Pressure in Lean and Obese Individuals. J Am Coll Cardiol. 2021 May 11;77(18):2291-2303. doi: 10.1016/j.jacc.2021.03.291. PubMed 33958126 ↗
  • Arora P, Wu C, Hamid T, Arora G, Agha O, Allen K, Tainsh RET, Hu D, Ryan RA, Domian IJ, Buys ES, Bloch DB, Prabhu SD, Bloch KD, Newton-Cheh C, Wang TJ. Acute Metabolic Influences on the Natriuretic Peptide System in Humans. J Am Coll Cardiol. 2016 Feb 23;67(7):804-812. doi: 10.1016/j.jacc.2015.11.049. PubMed 26892417 ↗
  • Bajaj NS, Gutierrez OM, Arora G, Judd SE, Patel N, Bennett A, Prabhu SD, Howard G, Howard VJ, Cushman M, Arora P. Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. JAMA Cardiol. 2018 Jan 1;3(1):11-17. doi: 10.1001/jamacardio.2017.4207. PubMed 29167879 ↗
  • Arora P, Reingold J, Baggish A, Guanaga DP, Wu C, Ghorbani A, Song Y, Chen-Tournaux A, Khan AM, Tainsh LT, Buys ES, Williams JS, Heublein DM, Burnett JC, Semigran MJ, Bloch KD, Scherrer-Crosbie M, Newton-Cheh C, Kaplan LM, Wang TJ. Weight loss, saline loading, and the natriuretic peptide system. J Am Heart Assoc. 2015 Jan 16;4(1):e001265. doi: 10.1161/JAHA.114.001265. PubMed 25595796 ↗
  • Parcha V, Kalra R, Li P, Oparil S, Arora G, Arora P. Nocturnal blood pressure dipping in treated hypertensives: insights from the SPRINT trial. Eur J Prev Cardiol. 2022 Feb 19;29(1):e25-e28. doi: 10.1093/eurjpc/zwaa125. No abstract available. PubMed 33624057 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jan 2027, 58 months after the start.

Of 33 non-industry phase 2/3 interventional studies under Obesity, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 53. This study's planned 58 months is above that.

Counting every sponsor, half of 36 studies reached it within 47 months; a quarter within 30 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2021
First posted
Jul 21, 2021
StartActual
Feb 18, 2022
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04971720
Responsible party
Pankaj Arora, MD (Assistant Professor, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham) — Principal investigator
First posted
Jul 21, 2021
Start date
Feb 18, 2022
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Nehal Vekariya, MS
Contact
nvekariya@uabmc.edu
205-934-7173
Deborah Weber, BSN, RN
Contact
dlowe@uabmc.edu
205-975-9964
Pankaj Arora, MD, FAHA
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion